Overview

Corporate Profile
Our success is supported by a proven strategy of marketing high-growth, innovative products, building our marketing and distribution channels, and investing in unique compounds that may change the course of disease. Our strategy balances the risk in our business and further distinguishes Cephalon from the majority of its peers.

Webcast ImageWebcast
Cephalon, Inc. at Stifel Nicolaus/Thomas Weisel Partners Healthcare Conference (Live)
09/15/10 at 3:15 p.m. ET
Cephalon, Inc. at Stifel Nicolaus/Thomas Weisel Partners Healthcare Conference
Wednesday, September 15, 2010 3:15 p.m. ET  
Webcast PresentationHelp Help
Listen to the Webcast in Windows Media Player Listen to the Webcast in Real Player Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Stock Quote
CEPH (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$59.43
Change (%) Stock is Up 0.01 (0.02%)
Volume180,524
Data as of 09/02/10 10:08 a.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
RSS Feeds RSS
More >>
DateTitle 
08/25/10Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
FRAZER, Pa., Aug 25, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc., (Nasdaq: CEPH) today announced Frank Baldino, Jr., Ph.D., the company's Chairman and Chief Executive Officer, will take a temporary medical leave of absence, effective immediately. During Dr. Baldino's absence, J. Kevin Buchi, the company's Chief Operating Officer, will assume Dr. Baldino's responsibilities. Prior to assuming the newly-created role of Chief Operating Officer earlier this year, Mr. Buchi served as the company's... 
Printer Friendly Version
07/27/10Cephalon Reports Record Sales and Earnings in Second Quarter 2010
Quarterly Sales of $712 Million Increased 32 Percent Quarterly Basic Adjusted EPS of $2.20 Increased 41 Percent Ex-US Sales Exceed 25 Percent of Worldwide Sales for the First Time FRAZER, Pa., July 27, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2010 sales of $712.4 million, a 32 percent increase compared to sales of $539.0 million for the second quarter 2009. Basic income per common share for the quarter was $1.18. Excluding amortizat... 
Printer Friendly Version
07/21/10Cephalon Expects Second Quarter 2010 Results to Exceed Previously Issued Guidance
FRAZER, Pa., July 21, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that, based on preliminary financial results, it expects sales and basic adjusted income per common share for the second quarter 2010 to exceed its previously issued guidance driven largely by strong product sales. The company now anticipates that sales for the second quarter 2010 will be between $705-715 million, up from the previous sales guidance of $645-670 million, resulting in basic adjusted... 
Printer Friendly Version
06/24/10Cephalon Second Quarter 2010 Earnings Conference Call Tuesday, July 27, 2010 at 5:00 p.m. EDT
FRAZER, Pa., June 24, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) has scheduled its regular quarterly earnings conference call covering second quarter 2010 results for 5:00 p.m. EDT on Tuesday, July 27, 2010. July 27, 2010 Schedule 4:10 p.m. EDT Q2 2010 results will be distributed by PRNewswire 4:50 p.m. EDT To participate in the conference call, dial 913-312-1497 and refer to Conference Code Number 3249552 5:00 p.m. EDT ... 
Printer Friendly Version
Investor EventsMore >>
DateTitle
09/15/10 3:15 p.m. ET
Cephalon, Inc. at Stifel Nicolaus/Thomas Weisel Partners Healthcare Conference
LocationBoston, MA
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.


Print Page Print Page | E-mail Page Email Page | RSS Feeds RSS Feeds | Financial Tear Sheet Financial Tear Sheet